bioRxivImmunologyPreprint
Overlapping MHC class I/II Epitopes Program cDC1-like Differentiation of Monocyte-Derived Dendritic Cells via mTORC1 Signaling Inhibition
Sharon Bright AmanyaiD, Arnav Murthy, Nalini BishtiD, Zaniqua N. BullockiD, Keenan ErnsteiD, Jonathan Vazquez‐PereziD, W. Liu, Akshar J. Trivedi, Damilola Oyewole-SaidiD, A Paul, Leilani Umokoro, Viktor AkhanoviD, Melanie A. SamueliD, Zhongcheng ShiiD, Michael NguyeniD, S Huang, M Jeong, P Iakova, KA Jain, K Pham, Daniel C. KraushaariD, Vanaja KonduriiD, WK Decker
Abstract
Viral infection polarizes monocyte-derived dendritic cells (moDC) to initiate type 1 immunity. The availability of overlapping (homologous) MHC class I and II epitopes, an occurrence frequently and primarily associated with intracellular infection, significantly enhances this process; however, the underlying mechanism(s) are unclear. We demonstrate that moDC loaded with homologous MHC epitopes acquire a cDC1-like phenotype in a process governed by mTORC1. mTORC1 pathway inhibition leads to NF-{kappa}B-mediated expression of IL-12 and other type I immune polarizing genes. The observed cDC1-like gene signature was also significantly enhanced in clinical moDC vaccine products made through methodologies that enforced class I and II antigenic homology. Collectively, these findings reveal a novel and previously unrecognized mechanism of immune governance that might also be exploited in cancer immunotherapy. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=167 SRC="FIGDIR/small/716309v1_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@15475borg.highwire.dtl.DTLVardef@ffe5fborg.highwire.dtl.DTLVardef@53c761org.highwire.dtl.DTLVardef@46c4ef_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy
Josue Estiven Pineda, Tomoyuki Minowa, … Matthew M. Gubin·The Journal of ImmunologyPeer-reviewed·Aug 1, 2026
- Conventional dendritic cells 2, the targeted antigen-presenting-cell, induces enhanced type 1 immune responses in mice immunized with CVC1302 in oil formulation
- Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset
Allison E. DePuyt, Peter E. J. Shoucair, … Robbie B. Mailliard·bioRxiv·May 2, 2026
- GM-CSF-activated human dendritic cells promote type1 T follicular helper cells (Tfh1) polarization in a CD40-dependent manner
S. Korniotis, M. Saichi, … V. Soumelis·bioRxiv·Apr 28, 2022
- A single MHCII neoepitope mRNA vaccine elicits CD4 T- and B- cell responses promoting endogenous CD8 anti-tumor immunity
Aude-Hélène Capietto, Camille-Charlotte Balança, … Jonathan L. Linehan·bioRxiv·Jun 9, 2025
- T cells compete via reverse MHC class I signaling at the synapse with dendritic cells to secure Golgi recruitment for activation
Anthi Psoma, Elke M. Muntjewerff, … Geert van den Bogaart·bioRxiv·May 15, 2026